SCHEMBL3137732

SCHEMBL3137732

O=C(NS(=O)(=O)c1cccc(Cl)c1)c1cccc(-n2cnc3c(NC4CC4)nc(C(F)(F)F)nc32)c1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 2/20 0.41
FLT1 P17948 2/20 0.38
FLT4 P35916 2/20 0.38
KDR P35968 2/20 0.38
ABL1 P00519 2/20 0.37
SRC P12931 2/20 0.37
PTGER1 P34995 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
PPARG P37231 3/20 0.35
FBP1 P09467 1/20 0.35
MCL1 Q07820 1/20 0.35
XDH P47989 1/20 0.35
STS P08842 1/20 0.34
CDK1 P06493 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3141046 0.92 YTHDC1 (0.41) YTHDC1ABL1SRCPTGER1PPARG
SCHEMBL3142068 0.89 YTHDC1 (0.38) YTHDC1ABL1SRCPTGER1PPARG
SCHEMBL3141117 0.88 YTHDC1 (0.39) YTHDC1ABL1SRCCDK1
SCHEMBL3133712 0.87 PPARG (0.40) YTHDC1ABL1SRCPPARG
SCHEMBL3141415 0.86 YTHDC1 (0.42) YTHDC1ABL1SRCCDK1
SCHEMBL3145969 0.85 YTHDC1 (0.41) YTHDC1ABL1SRCCDK1
SCHEMBL3137619 0.85 PTGER3 (0.38) YTHDC1ABL1SRCHDAC8HDAC6
SCHEMBL3145999 0.84 YTHDC1 (0.37) YTHDC1ABL1SRCHDAC8
SCHEMBL3130221 0.84 PFKFB4 (0.42) YTHDC1
SCHEMBL3140949 0.84 ABL1 (0.38) YTHDC1ABL1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004236-A1 PHOSPHODIESTERASE 4 INHIBITORS TEHIM ASHOK 2010-01-07 US claimed
US-20080139583-A1 PHOSPHODIESTERASE 4 INHIBITORS TEHIM ASHOK 2008-06-12 US claimed
US-7332486-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2008-02-19 US claimed
US-20070093510-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-26 US claimed
US-20100004236-A1 PHOSPHODIESTERASE 4 INHIBITORS TEHIM ASHOK 2010-01-07 US disclosed
EP-1529049-B1 DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARM CORP (US) 2009-11-18 EP disclosed
WO-2009067607-A2 COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS MEMORY PHARMACEUTICALS CORPORATION (US) 2009-05-28 WO disclosed
US-20080139583-A1 PHOSPHODIESTERASE 4 INHIBITORS TEHIM ASHOK 2008-06-12 US disclosed
US-7332486-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2008-02-19 US disclosed
US-20070093510-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093510-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE3B, PDE3A YTHDC1 3986/4885FLT1 666/4885FLT4 321/4885
US-20080139583-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE3A YTHDC1 3986/4885FLT1 666/4885FLT4 321/4885
US-20100004236-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE3B, PDE3A YTHDC1 3986/4885FLT1 666/4885FLT4 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.